These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004 [TBL] [Abstract][Full Text] [Related]
71. Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy. Aggarwal C; Ben-Shachar R; Gao Y; Hyun SW; Rivers Z; Epstein C; Kaneva K; Sangli C; Nimeiri H; Patel J JAMA Netw Open; 2023 May; 6(5):e2311181. PubMed ID: 37129893 [TBL] [Abstract][Full Text] [Related]
72. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer. Hata A; Katakami N; Nanjo S; Okuda C; Kaji R; Masago K; Fujita S; Yoshida H; Zama K; Imai Y; Hirata Y Lung Cancer; 2017 Sep; 111():182-189. PubMed ID: 28838391 [TBL] [Abstract][Full Text] [Related]
73. Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study. Zhang Y; Song L; Zeng L; Xiong Y; Liu L; Zhou C; Yang H; Wang Z; Xia Q; Jiang W; Xu Q; Yang N BMC Cancer; 2022 Sep; 22(1):952. PubMed ID: 36064386 [TBL] [Abstract][Full Text] [Related]
74. Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. Abdel-Rahman O Crit Rev Oncol Hematol; 2016 May; 101():75-85. PubMed ID: 26969107 [TBL] [Abstract][Full Text] [Related]
75. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. Bjørnhart B; Hansen KH; Jørgensen TL; Herrstedt J; Schytte T Acta Oncol; 2019 Jul; 58(7):953-961. PubMed ID: 31081424 [No Abstract] [Full Text] [Related]
76. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker. He B; Dong D; She Y; Zhou C; Fang M; Zhu Y; Zhang H; Huang Z; Jiang T; Tian J; Chen C J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636239 [TBL] [Abstract][Full Text] [Related]
77. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. Ahn BC; Pyo KH; Xin CF; Jung D; Shim HS; Lee CY; Park SY; Yoon HI; Hong MH; Cho BC; Kim HR J Cancer Res Clin Oncol; 2019 Jun; 145(6):1613-1623. PubMed ID: 30911841 [TBL] [Abstract][Full Text] [Related]
78. The efficacy of PD-1/PD-L1 inhibitors in advanced squamous-cell lung cancer: a meta-analysis of 3112 patients. Chen RL; Zhou JX; Cao Y; Li SH; Li YH; Jiang M; Lu DY; Li P; Lin LZ Immunotherapy; 2019 Dec; 11(17):1481-1490. PubMed ID: 31713453 [No Abstract] [Full Text] [Related]
79. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis. Miyashita K; Karayama M; Inoue Y; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Kono M; Matsui T; Niwa M; Koda K; Toyoshima M; Matsushima S; Matsuura S; Asada K; Fujii M; Kusagaya H; Matsuda H; Inui N; Suda T BMC Pulm Med; 2021 Oct; 21(1):309. PubMed ID: 34600514 [TBL] [Abstract][Full Text] [Related]
80. PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. Meniawy TM; Lake RA; McDonnell AM; Millward MJ; Nowak AK Lung Cancer; 2016 Mar; 93():9-16. PubMed ID: 26898608 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]